Onasemnogene abeparvovec for spinal muscular atrophies of childhood

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 12 Feb 2019: Trial registered, NCT03837184
  2. 31 May 2019: Trial started, NCT03837184

The trials

NCT02122952: Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1

State
Completed
Phase
Phase 1
People
15 taking part
Started
5 May 2014
Primary completion
15 Dec 2017
Arms
Cohort 1, Cohort 2
Results
Posted on the registry
  1. 25 Apr 2014: Trial registered
  2. 5 May 2014: Trial started
  3. 15 Dec 2017: Trial completed
  4. 10 May 2019: Trial results posted

NCT03837184: Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

State
Completed
Phase
Phase 3
People
2 taking part
Started
31 May 2019
Primary completion
29 Jun 2021
Arms
Onasemnogene Abeparvovec-xioi
Results
Posted on the registry
  1. 12 Feb 2019: Trial registered
  2. 31 May 2019: Trial started
  3. 29 Jun 2021: Trial completed
  4. 11 Jan 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Onasemnogene Abeparvovec-xioi, Zolgensma.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.